Abstract
Transforming growth factor beta (TGF-β) induced myofibroblast differentiation is central to the pathological scarring observed in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. Our lab has recently identified expression of GPR68 (Ovarian Cancer Gene Receptor 1, OGR1), a pH sensing G-protein coupled receptor, as a negative regulator of TGF-β induced profibrotic effects in primary human lung fibroblasts (PHLFs). We therefore hypothesized that small molecule activators of GPR68 would inhibit myofibroblast differentiation. Ogerin is a positive allosteric modulator (PAM) of GPR68, inducing a leftward shift of the dose response curve to proton induced signaling. Using PHLFs derived from patients with both non-fibrotic and IPF diagnoses, we show that Ogerin inhibits, and partially reverses TGF-β induced myofibroblast differentiation in a dose dependent manner. This occurs at the transcriptional level without inhibition of canonical TGF-β induced SMAD signaling. Ogerin induces PKA dependent CREB phosphorylation, a marker of Gαs pathway activation. The ability of Ogerin to inhibit both basal and TGF-β induced collagen gene transcription, and induction of Gαs signaling is enhanced at an acidic pH (pH 6.8). Similar findings were also found using fibroblasts derived from dermal, intestinal, and orbital tissue. The biological role of GPR68 in different tissues, cell types, and disease states is an evolving and emerging field. This work adds to the understanding of Gαs coupled GPCRs in fibrotic lung disease, the ability to harness the pH sensing properties of GPR68, and conserved mechanisms of fibrosis across different organ systems.
Funder
National Institute of Environmental Health Sciences
National Heart, Lung, and Blood Institute
Boehringer Ingelheim
Publisher
Public Library of Science (PLoS)
Reference124 articles.
1. Cellular and molecular mechanisms of fibrosis;T.A. Wynn;J Pathol,2008
2. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases;T.A. Wynn;The Journal of Clinical Investigation,2007
3. Fibrotic disease and the T(H)1/T(H)2 paradigm.;T.A. Wynn;Nature reviews. Immunology,2004
4. Identifying common genes and networks in multi-organ fibrosis;K.E. Wenzke;AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science,2012
5. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.;C.B. Nanthakumar;Nat Rev Drug Discov,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献